FDA approves new breakthrough therapy for cystic fibrosis

Treatment approved for approximately 90% of patients with cystic fibrosis, many of whom had no approved therapeutic options Source FDA The U.S. Food and Drug Administration today approved Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triple combination therapy available to treat patients with the most common cystic fibrosis mutation. Trikafta is approved for patients 12 years and older

Read More


Thirty patient deaths tied to cystic fibrosis drug following FDA database of side effects

Thirty patients have died after taking Symdeko, a Vertex Pharmaceuticals treatment for cystic fibrosis, according to a government database. The deaths, reported to the Food and Drug Administration’s database of side effects, are tied to Symdeko, a Vertex medicine approved last year. Reports to the database are commonly submitted by health care professionals and often contain

Read More